medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (4)


The role of hepatitis B immunoglobulin in hepatitis B related liver transplantation: Canadian Transplant Centre Position Paper

Levstik M, Wong P, Greanya ED, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 441-444
Archivo PDF: 38.19 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Canadian Organ Replacement Register (CORR). Canadian Institute for Health Information. Health Services Databases. Available from: http://www.cihi.ca

  2. Gane E. Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: high, low or no dose. Liver Transplant 2010; 16: S36-S39.

  3. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-47.

  4. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, Mc- Cullough CS, Dickson RC, Caldwell SH, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-64.

  5. Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N, Cantarovich M, et al. Recurrence-free longterm survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997; 226: 356-65.

  6. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968-74.

  7. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and result. J Hepatol 2003; 39: S181-S189.

  8. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-95.

  9. Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endoscytosis of hepatitis B immunoglobulin into hepatocytes inhibiti the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77: 8882-92.

  10. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-33.

  11. Samuel D. The option of liver transplantation for hepatitis B: Where are we? Digest Liver Dis 2009; 41S: S185-S189.

  12. Terrault NA, Kilic M, Karademir S, Karasu Z, Astarcioglu I, Genereux M, Dixit J, et al. HepaGam B after liver transplant in patients with hepatitis B virus. US Gastroenterol Rev 2007; 2: 39-45.

  13. Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol 2010; 9: 166-71.

  14. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, Eggen HJ, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-5.

  15. Canadian Transplant HBIg Forum, August 13, 2010, Vancouver, BC.

  16. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.

  17. Teperman L, Spivey J, Poordad F, Schiano T, Bzowej N, Pungpapong S, Martin P, et al. Emtricitabine/tenofovir combination +/- HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment. J Hepatol 2010; 52: S12-S13.

  18. Gane E, Strasser S, Patterson S, McCaughan G, Angus P. A prospective study on the safety and efficacy of lamivudine and adefovir prophylaxis in HBsAg positive liver transplantation candidates. Hepatology 2007; 46: 479A.

  19. Hadziyannis S, Tassopoulos N, Chang TT. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: Results after 5 years of therapy [Abstract]. Hepatology 2005; 42: 754A.

  20. Borroto-Esoda K, Arterburn S, Snow A. Final analysis of the virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients. J Hepatol 2006; 44: S179-S180.

  21. Colonno RJ, Rose RE, Pokornowski. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology 2006; 44: 229A-230A.

  22. Powell JJ, Apiratpracha W, Partovi N, Erb SR, Scudamore CH, Steinbrecher UP, Buczkowski AK, et al. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant 2006; 20: 524-5.




2020     |     www.medigraphic.com